Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Relmada Therapeutics, Inc./ S-3

SEC Filing · S-3

Relmada Therapeutics, Inc.

RLMDNASDAQEQUITYCurrent

SEC Filing

Filed Apr 3, 2026Accepted Apr 3, 2026, 4:30 PM EDTCIK 1553643Accession 0001213900-26-039967
View company →Permanent SEC source ↗
Share

Company context

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

Current securities

RLMDNASDAQ · EQUITY · Current

Recent company filings

  1. Other EventsSep 8, 2026
  2. SCHEDULE 13G/A - filed by Squadron Capital Management LLC regarding RELMADA THERAPEUTICS, INC.Aug 14, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureAug 6, 2026
  4. 10-Q filingAug 6, 2026
  5. Regulation FD DisclosureJul 28, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.